Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis Inc. (NASDAQ: CRIS) is a biotechnology company dedicated to the development and commercialization of groundbreaking drug candidates aimed at treating human cancers. Established as a significant player in the biotech sector, Curis is renowned for its focus on immuno-oncology and precision oncology therapeutic areas.
Core Business and Pipeline
Curis's pipeline is robust, featuring a number of promising drug candidates. One of its leading drugs is Emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor currently undergoing clinical trials. The trials include the Phase 1/2 TakeAim Lymphoma study, which targets hematologic malignancies such as non-Hodgkin's lymphoma, and the Phase 1/2 TakeAim Leukemia study aimed at acute myeloid leukemia and myelodysplastic syndrome. Emavusertib has already received Orphan Drug Designation from the U.S. Food and Drug Administration.
Curis is also investigating other candidates such as CUDC-907, which focuses on relapsed or refractory diffuse large B-cell lymphoma with alterations in the MYC oncogene, and other small molecule antagonists like CA-170 and CA-327, designed to inhibit pathways such as PD1, VISTA, and TIM3.
Collaborations & Partnerships
Curis has forged a strategic collaboration with Aurigene, granting it exclusive licenses to several promising molecules. This partnership enhances Curis's ability to innovate in the areas of immuno-oncology and precision oncology, specifically with oral small molecule antagonists. Additionally, Curis has licensed its rights to Erivedge® to Genentech, which is commercializing the drug for advanced basal cell carcinoma under the Roche Group.
Recent Achievements and Financial Condition
Curis has recently presented data from multiple clinical studies at prestigious conferences such as the American Society of Hematology (ASH) and the European Hematology Association (EHA), showcasing promising results from its ongoing trials. The company reported a net loss of $47.4 million for the year ended December 31, 2023, but continues to maintain a strong cash position with $56.3 million in cash, cash equivalents, and investments.
Curis's ongoing research and development efforts are backed by substantial funding and strategic partnerships, enabling the company to sustain its operations and advance its pipeline into the year 2025.
For more information, visit Curis's website at www.curis.com.
Curis, Inc. (NASDAQ: CRIS) announced a virtual symposium titled "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond", occurring on June 18, 2021. The event will feature discussions on the emerging checkpoint molecule VISTA, its implications in various diseases, and ongoing development programs, including Curis's anti-VISTA antibody, CI-8993, currently in clinical trials. Notable speakers include Dr. Randolph Noelle and Dr. Padmanee Sharma. Attendees will explore topics such as checkpoint therapy, VISTA's role in the tumor microenvironment, and advances in clinical development.
Curis, a biotechnology company specializing in cancer therapeutics, announced that its CEO, James Dentzer, will participate in a virtual fireside chat at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 3:00 p.m. ET. The event will be available via live webcast on Curis' investor website, with a replay for 90 days post-event. Curis is known for its research in immuno-oncology and precision oncology, including ongoing trials for CA-4948, targeting various forms of cancer.
Curis, Inc. (NASDAQ: CRIS) reported its Q1 2021 results, marking a net loss of $9.9 million or $0.11 per share. Revenues declined to $2.2 million from $2.7 million in Q1 2020. Operational highlights include progress on CA-4948, which expanded into new clinical trials, receiving Orphan Drug designation from the FDA for AML and MDS, and promising early results in ongoing studies. Cash reserves stood at $168.4 million, expected to sustain operations into 2024. The company plans to share more clinical data at the EHA Congress and future trials in the second half of 2021.
Curis, Inc. (NASDAQ: CRIS) announced two abstracts for CA-4948 accepted for presentation at the European Hematology Association 2021 Virtual Congress from June 9-17, 2021. CA-4948 is an IRAK4 inhibitor in a Phase 1/2 study targeting acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Key findings from 15 patients included a 89% blast reduction in evaluable patients and notable hematologic responses. Curis anticipates presenting additional data on safety and efficacy at the congress.
Curis, a biotechnology company focused on cancer therapeutics, will release its first quarter 2021 financial results on May 12, 2021, after US market close. A conference call is scheduled for 4:30 pm ET on the same day to discuss the results. The company is engaged in multiple collaborations and clinical trials, including CA-4948 for non-Hodgkin lymphoma and other conditions, as well as ongoing trials for CI-8993. Investors can access the call via phone or the Curis website.
Curis, Inc. (NASDAQ: CRIS) announced that the FDA has granted Orphan Drug designation for CA-4948, a small molecule inhibitor targeting IRAK4, primarily for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This designation offers benefits like seven years of market exclusivity and FDA support in clinical trials. The drug has shown broad clinical activity in Phase 1 trials for relapsed or refractory AML/MDS. CEO James Dentzer highlighted this as a significant milestone in addressing rare hematological malignancies.
Curis, Inc. (NASDAQ: CRIS) announced on April 1, 2021, the grant of inducement stock options for 167,300 shares to five new employees. The options have a ten-year term, with an exercise price equal to the closing stock price on the grant date. Vesting occurs over four years, starting with 25% after one year. This grant is meant to incentivize new hires and is categorized as an inducement award outside the company’s existing stock plan. Curis focuses on cancer therapeutics and has collaborations with various partners for drug development.
Curis, a biotechnology company focused on cancer therapeutics, announced that CEO James Dentzer will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 10:15 am ET. A live webcast will be available on the company's website, with a replay accessible for 90 days. Curis has ongoing collaborations in immuno-oncology, including testing CA-4948 in lymphomas and leukemia, and developing CI-8993 for solid tumors. The company also collaborates with Genentech for Erivedge, a treatment for advanced basal cell carcinoma.
Curis (NASDAQ: CRIS) reported its financial results for Q4 and the year ended December 31, 2020. The company achieved revenues of $10.8 million, up from $10.0 million in 2019. Net loss was $29.9 million, improving from a $32.1 million loss in 2019. Notable developments included positive Phase 1 trial results for CA-4948, showing effectiveness in patients with AML and high-risk MDS. Curis has sufficient cash resources of $183.1 million to support operations into 2024 and looks forward to multiple clinical data readouts throughout 2021.
Curis, Inc. (NASDAQ: CRIS) announced that an abstract for its IRAK4 inhibitor, CA-4948, has been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 10-15, 2021. The presentation, titled Identification of NF-kappaB phospho-p50 as a Potential Predictive Biomarker for IRAK4 inhibitor CA-4948 in Patients with Non-Hodgkin's Lymphoma, falls under the Biomarkers Predictive of Therapeutic Benefit session. CA-4948 is currently in Phase 1 trials for non-Hodgkin's lymphoma and acute myeloid leukemia.
FAQ
What is the current stock price of Curis (CRIS)?
What is the market cap of Curis (CRIS)?
What is Curis Inc.'s focus in the biotechnology sector?
What are some of the key drug candidates in Curis's pipeline?
What significant collaborations does Curis have?
What is the current status of Emavusertib's clinical trials?
How is Curis performing financially?
What recent achievements has Curis reported?
What is the significance of Curis's collaboration with Aurigene?
What role does Genentech play in Curis's portfolio?
What are Curis's future plans for its drug pipeline?
Where can I find more information about Curis Inc.?
